title: Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies.
abstract: Stroke still remains a major healthcare problem. The growing understanding of the mechanism of cell death in ischemia leads to new approaches in stroke treatment. The aim of neuroprotection is to reduce the post-stroke impairment and the overall costs that are accompanied in patients with severe disability. Despite encouraging data from experimental animal models, almost all neuroprotective therapies have, to date, not been established in clinical routine. In this part B of our review on stroke therapies we provide an overview on future candidates in stroke therapy and neuroprotective agents that are under investigation.
authors.affiliation: Paracelus Medical University Salzburg, Christian-Doppler-Klinik, Department of Neurology, Ignaz-Harrer Strasse 79, 5020 Salzburg, Austria. e.broussalis@salk.at
authors.forename: Erasmia
authors.initials: E
authors.lastname: Broussalis
authors.forename: Eugen
authors.initials: E
authors.lastname: Trinka
authors.forename: Monika
authors.initials: M
authors.lastname: Killer
authors.forename: Andrea
authors.initials: A
authors.lastname: Harrer
authors.forename: Mark
authors.initials: M
authors.lastname: McCoy
authors.forename: Jörg
authors.initials: J
authors.lastname: Kraus
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D020767:Intracranial Thrombosis / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D015507:Drugs, Investigational; D018696:Neuroprotective Agents